A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

GLP-RAs significantly improved liver histology, liver fat, and metabolic markers in patients with MASLD, outperforming DDP-4 inhibitors but increasing mild GI side effects.

GLP-1s may confer greater protection from major adverse cardiovascular events compared with sulfonylureas, ...

Patients with systemic lupus erythematosus (SLE) and type 2 diabetes, with and without lupus nephritis (LN), had a lower risk of serious cardiovascular and kidney diseases when they took GLP-1 ...

GLP-1 is a natural human hormone that regulates blood glucose levels. Scientists have now created long-lasting GLP-1 drugs ...

Relative to GLP-1RA and DPP-4 inhibitor use, SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not an increased risk for thrombosis in T2D. Among individuals with type 2 ...

Moderate-risk patients with diabetes treated with a sulfonylurea appear to be at a higher risk of major adverse cardiovascular events than those who receive a dipeptidyl peptidase-4 (DPP-4) inhibitor, ...

So the, the question we're investigating in this study is whether the use of GLP-1 receptor agonists, which is *** medication for weight loss and diabetes, um, is associated with *** lower risk of ...

Medicaid enrollees with type 2 diabetes (T2D) continue to face restricted access to newer cardioprotective diabetes medications — sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like ...

The latest data from academics, physicians, and pharmaceutical-company scientists gathered at the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) in Bethesda for the past 2 days ...